BR112016020366A2 - anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais - Google Patents

anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais

Info

Publication number
BR112016020366A2
BR112016020366A2 BR112016020366A BR112016020366A BR112016020366A2 BR 112016020366 A2 BR112016020366 A2 BR 112016020366A2 BR 112016020366 A BR112016020366 A BR 112016020366A BR 112016020366 A BR112016020366 A BR 112016020366A BR 112016020366 A2 BR112016020366 A2 BR 112016020366A2
Authority
BR
Brazil
Prior art keywords
antibodies
eotaxin
disorders
ccr3
recognize additional
Prior art date
Application number
BR112016020366A
Other languages
English (en)
Other versions
BR112016020366B1 (pt
Inventor
Mor Adi
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of BR112016020366A2 publication Critical patent/BR112016020366A2/pt
Publication of BR112016020366B1 publication Critical patent/BR112016020366B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)

Abstract

a invenção refere-se a anticorpos isolados poliespecíficos dirigidos a um epítopo exclusivo na quimiocina eotaxina 2, em que os anticorpos se ligam às quimiocinas de ligação a ccr3. a invenção também diz respeito à utilização desses anticorpos para atenuar a migração de várias células e para o tratamento de doenças fibróticas, distúrbios inflamatórias autoimunes, distúrbios relacionados a monócitos ou distúrbios atópicos alérgicos.
BR112016020366-6A 2014-03-04 2015-03-04 Anticorpo isolado que se liga a uma quimiocina de ligação a ccr3, molécula de ácido nucleico, vetor de expressão, célula hospedeira microbiana, e composição farmacêutica BR112016020366B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947852P 2014-03-04 2014-03-04
US61/947,852 2014-03-04
PCT/IL2015/050234 WO2015132790A2 (en) 2014-03-04 2015-03-04 Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines

Publications (2)

Publication Number Publication Date
BR112016020366A2 true BR112016020366A2 (pt) 2018-06-05
BR112016020366B1 BR112016020366B1 (pt) 2024-01-02

Family

ID=52815066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016020366-6A BR112016020366B1 (pt) 2014-03-04 2015-03-04 Anticorpo isolado que se liga a uma quimiocina de ligação a ccr3, molécula de ácido nucleico, vetor de expressão, célula hospedeira microbiana, e composição farmacêutica

Country Status (11)

Country Link
US (2) US10246508B2 (pt)
EP (2) EP4155317A1 (pt)
JP (1) JP6553075B2 (pt)
CN (1) CN106103479B (pt)
BR (1) BR112016020366B1 (pt)
DK (1) DK3114139T3 (pt)
ES (1) ES2926700T3 (pt)
IL (1) IL247219B (pt)
PT (1) PT3114139T (pt)
RU (1) RU2705255C2 (pt)
WO (1) WO2015132790A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017183028A1 (en) * 2016-04-18 2017-10-26 Chemomab Ltd. Eotaxin-2 inhibitors in the treatment of fibromyalgia
EP3551046B1 (en) 2016-12-07 2023-07-19 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018139404A1 (ja) 2017-01-24 2018-08-02 協和発酵キリン株式会社 放射線障害の治療又は予防剤並びに治療又は予防方法
GB201702500D0 (en) * 2017-02-16 2017-04-05 Univ Sheffield Stable vamp reporter assay
IL251024A0 (en) * 2017-03-08 2017-06-29 Chemomab Ltd Antibodies against eutaxin 2 for use in the treatment of liver diseases
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
US10945904B2 (en) 2019-03-08 2021-03-16 Auris Health, Inc. Tilt mechanisms for medical systems and applications
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230192836A1 (en) 2020-04-20 2023-06-22 Chemomab Ltd. Ccl24 inhibitors in the treatment of covid-19
AU2021259682A1 (en) 2020-04-22 2022-10-20 Chemomab Ltd. Method of treatment using anti-CCL24 antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303736B1 (it) * 1998-11-11 2001-02-23 San Raffaele Centro Fond Peptidi derivati da rantes con attivita' anti-hiv.
RU2458918C2 (ru) * 2006-07-22 2012-08-20 Оксаген Лимитед Соединения, обладающие антагонистической активностью по отношению к crth2
AU2010209273A1 (en) * 2009-01-28 2011-09-01 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
ES2531561T3 (es) 2009-08-28 2015-03-17 Regeneron Pharmaceuticals, Inc. Anticuerpos de antiquina que se enlazan a múltiples quimioquinas CC
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid

Also Published As

Publication number Publication date
WO2015132790A3 (en) 2015-11-05
RU2016136639A3 (pt) 2018-05-04
BR112016020366B1 (pt) 2024-01-02
EP4155317A1 (en) 2023-03-29
IL247219B (en) 2021-09-30
RU2016136639A (ru) 2018-04-05
PT3114139T (pt) 2022-09-13
CN106103479B (zh) 2019-12-24
EP3114139B1 (en) 2022-06-15
US10479830B2 (en) 2019-11-19
DK3114139T3 (da) 2022-09-12
RU2705255C2 (ru) 2019-11-06
US10246508B2 (en) 2019-04-02
WO2015132790A2 (en) 2015-09-11
ES2926700T3 (es) 2022-10-27
JP2017508461A (ja) 2017-03-30
US20190153088A1 (en) 2019-05-23
IL247219A0 (en) 2016-09-29
US20160368979A1 (en) 2016-12-22
JP6553075B2 (ja) 2019-08-07
CN106103479A (zh) 2016-11-09
EP3114139A2 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
BR112016020366A2 (pt) anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais
BR112016016436A2 (pt) moléculas de anticorpo para tim-3 e usos das mesmas
UY37779A (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
BR112018008891A8 (pt) anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
BR112018072389A2 (pt) anticorpos que reconhecem tau
BR112018013728A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações imunitárias
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
CO2017008476A2 (es) Anticuerpos anti-transtiretina
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
BR112018072394A2 (pt) anticorpos que reconhecem a tau
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
EA201691765A1 (ru) Молекулы антител против lag-3 и их применения
BR112019022906A2 (pt) Anticorpos que reconhecem tau
CO2017008482A2 (es) Anticuerpos anti-transtiretina
BR112017016324A2 (pt) anticorpos anti-transtiretina
CL2019000799A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433)
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
BR112016015881A2 (pt) Tecnologia inédita de adcc baseada em biologia sintética
BR112021025421A2 (pt) Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
BR112017003200A2 (pt) anticorpos de potenciamento do fator h e seus usos
EA201790920A1 (ru) Титрованные экстракты cynara scolymus и их применения
EA202090891A1 (ru) Молекулы антител против cd138 и их применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/03/2015, OBSERVADAS AS CONDICOES LEGAIS